Novavax, Inc. (NVAX) (“Novavax”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. Novavax…
10 Search Results for “covid-19”
Novavax, Inc. (NVAX) (“Novavax”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. Novavax…
CTI BioPharma (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI focuses on developing and commercializing Pacritinib, its product candidate…
Icosavax (the “Company”) is a biotechnology company developing virus-like particle (VLP) vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID19). The Company’s VLP platform technology is designed to enable a multivalent, particle-based display of complex viral antigens, which could induce broad, robust and durable protection against the specific targeted virus. Icosavax’s lead vaccine candidate, IVX-A12, is…
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel vaccines. Dynavax’s sole marketed product, HEPLISAV-B, was approved in November 2017 and launched in February 2018 for the prevention of infection caused by all known subtypes of Hepatitis B virus in adults age 18 years or older. Dynavax is…
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also developing CpG 1018 as an advanced vaccine…
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The Company has assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA. The Company’s current development pipeline consists of product candidates targeting severe…
Cue Health Inc. (“Cue Health” or the “Company”) is a health technology company that has developed a platform consisting of the following hardware and software components: (1) the Cue Health Monitoring System, made up of a portable, durable and reusable reader, a single-use test cartridge, and a sample collection wand, (2) the Cue Data and Innovation Layer, with cloud-based data…
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adult and pediatric patients 12 years…
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGETM, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can…